An observational study in Congenital Heart Disease (CHD), sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University Hospital Tuebingen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 31st registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:
Alexandra Miriam Kiess · Sites in Germany
Ages 6–18
Charite University, Berlin, Germany · Sites in Germany
Ages 0–18
Fondation Hôpital Saint-Joseph · Sites in Germany, Denmark, Egypt and 14 more countries
Ages 1 mo+
Deutsches Herzzentrum Muenchen · Sites in Germany
Ages 8–14
University Hospital, Bordeaux · Sites in Germany, Belgium, France
Ages 8–25
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 845 is above the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 70 across the 24 interventional studies, 300 across the 14 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Defects, Congenital with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT07716488Alexandra Miriam KiessScreening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders | 2027-01-31 |
| NCT06845371University Hospital TuebingenMELODY Registry Follow-Up Study | 2027-05-01 |
| NCT07193719Charite University, Berlin, GermanyInfluence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Extension of the MELODY Registry, to assess longterm follow-up clinical results of Melody valve implantation after its commercialization in Europe / OUS
Patients who underwent Melody valve implantation into the pulmonary position after its commercialization in Europe / OUS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
primary outcome
• composite endpoint of TPVI related follow-up events (i.e. death, reoperation, or reintervention \>48h after TPVI)
Time frame: from december 2006 up to December 2027
secondary measure
TPVI infective endocarditis (I.E.) according to modified Duke criteria n
Time frame: from december 2006 up to December 2027
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →